1. Home
  2. BAFN vs NVNO Comparison

BAFN vs NVNO Comparison

Compare BAFN & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BAFN
  • NVNO
  • Stock Information
  • Founded
  • BAFN 1999
  • NVNO 1987
  • Country
  • BAFN United States
  • NVNO United States
  • Employees
  • BAFN N/A
  • NVNO N/A
  • Industry
  • BAFN Savings Institutions
  • NVNO Medical/Dental Instruments
  • Sector
  • BAFN Finance
  • NVNO Health Care
  • Exchange
  • BAFN Nasdaq
  • NVNO Nasdaq
  • Market Cap
  • BAFN 61.9M
  • NVNO 41.0M
  • IPO Year
  • BAFN N/A
  • NVNO N/A
  • Fundamental
  • Price
  • BAFN $15.80
  • NVNO $3.63
  • Analyst Decision
  • BAFN
  • NVNO
  • Analyst Count
  • BAFN 0
  • NVNO 0
  • Target Price
  • BAFN N/A
  • NVNO N/A
  • AVG Volume (30 Days)
  • BAFN 10.0K
  • NVNO 76.2K
  • Earning Date
  • BAFN 04-24-2025
  • NVNO 05-01-2025
  • Dividend Yield
  • BAFN 1.95%
  • NVNO N/A
  • EPS Growth
  • BAFN 113.18
  • NVNO N/A
  • EPS
  • BAFN 2.34
  • NVNO N/A
  • Revenue
  • BAFN $80,167,000.00
  • NVNO N/A
  • Revenue This Year
  • BAFN N/A
  • NVNO N/A
  • Revenue Next Year
  • BAFN N/A
  • NVNO $409.09
  • P/E Ratio
  • BAFN $7.03
  • NVNO N/A
  • Revenue Growth
  • BAFN 2.60
  • NVNO N/A
  • 52 Week Low
  • BAFN $10.40
  • NVNO $2.03
  • 52 Week High
  • BAFN $19.75
  • NVNO $6.48
  • Technical
  • Relative Strength Index (RSI)
  • BAFN 51.67
  • NVNO 71.27
  • Support Level
  • BAFN $15.48
  • NVNO $2.61
  • Resistance Level
  • BAFN $17.45
  • NVNO $3.97
  • Average True Range (ATR)
  • BAFN 0.90
  • NVNO 0.22
  • MACD
  • BAFN 0.25
  • NVNO 0.13
  • Stochastic Oscillator
  • BAFN 55.41
  • NVNO 79.64

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About NVNO enVVeno Medical Corporation

enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Share on Social Networks: